Pinnacle Financial Group, Inc.’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Pinnacle Financial Group, Inc.'s CRSP Position: Q3 2026 in Review
Pinnacle Financial Group, Inc. opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 8,727 shares worth $483K. The stake represents 0.05% of the portfolio and ranks #282 among its holdings.
503 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Pinnacle Financial Group, Inc. held 8,727 shares of CRISPR Therapeutics worth $483K as of Q3 2026.
- CRISPR Therapeutics was a new Pinnacle Financial Group, Inc. position in Q3 2026.
- CRISPR Therapeutics made up 0.05% of Pinnacle Financial Group, Inc.'s portfolio in Q3 2026, its #282 holding.
- 503 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Pinnacle Financial Group, Inc.'s 13F filing for Q3 2026, filed 16 Nov 2026.